Jul 07

CTSI-Think Tank Seed Funds our Efforts to facilitate CAR-T Therapy to Treat Solid Tumors.

Breast Cancer is the most widespread cancer and the second leading cause of cancer-related deaths among women in the U.S.A. As a treatment option, gene-modified T cells are under active therapeutic consideration for both hematological and solid malignancies.  As of 2016, there are 17 active TCR and 103 ongoing CAR-modified T cell studies registered through clinicaltrials.gov. Chimeric antigen receptors (CAR) T-cells are attractive as the affinity of (CAR) T-cell to the tumor surface antigen can be made high through protein engineering thus, promoting  a strong anti-tumoral response. One of the biggest concern for efficient translation of CAR-T cells based therapies to solid tumors is the non-specific targeting of healthy tissue and organ systems, which have led to patient deaths.

The CTSI think-tank has seeded our nanoparticle technology that will increase specificity of CAR-T cells to their target and not to healthy off-target tissue.